Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol

National Medical Journal of China

Volumn 88, Issue 32, 2008, Pages 2254-2257

  Lu, Jin ^a   Jiang, Hao ^a   Jiang, Qian ^a   Bao, Li ^a   Lu, Xi Jing ^a   Zhang, Yan ^a   Lin, Wei ^a   Liu, Yan Rong ^a   Huang, Xiao Jun ^a   Jiang, Bin ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antibiotics, anthracycline; Chromosomes; Leukemia, myeloid; Red arsenic sulfide; Tretinoin

Indexed keywords

ANTHRACYCLINE; ARSENIC DERIVATIVE; RED ARSENIC SULFIDE; RETINOIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CENTRAL NERVOUS SYSTEM; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG RESPONSE; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; SURVIVAL RATE; TRISOMY 8;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CHROMOSOME ABERRATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SULFIDES; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 54949153064     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Zhou GB, Zhang J, Wang ZY, et al. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci, 2007, 362: 959-971.
2. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood, 2002, 99: 3136-3143.
3. Chinese source.
4. Chinese source.
5. Chinese source.
6. Chinese source.
7. Xu L, Zhao WL, Xiong SM, et al. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia, 2001, 15: 1359-1368.
8. Chinese source.
9. Hernández JM, Martín G, Gutiérrez NC, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica, 2001, 86: 807-813.
10. Chou WC, Tang JL, Yao M, et al. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia, 1997, 11: 921-928.
11. Wan TS, Ma SK, Au WY, et al. Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. Cancer Genet Cytogenet, 2003, 140: 170-173.
12. Slack JL, Arthur DC, Lawrence D, et al. Secondary cytogenetic changes in acute promyelocytic leukemia - prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol, 1997, 15: 1786-1795.